Mitral valve prolapse is the most frequent cause of mitral valve regurgitation and is associated to hospitalization for cardiac failure and mortality. At present, the preferred treatment for operable patients is mitral valve surgical repair. Transcatheter edge to edge repair (TEER) has shown great benefit patients at high surgical risk; however, it has not been<a href="https://solaci.org/en/2022/05/12/transcatheter-edge-to-edge-repair-is-favorable-for-elderly-patients-at-high-surgical-risk/" title="Read more" >...</a>
Is Increased Mitral Valve Gradient After MitraClip a Long-Term Prognostic Factor?
Transcatheter mitral valve repair using the edge-to-edge strategy has become a therapeutic alternative for patients with severe primary mitral valve regurgitation (MVG) who are at high or extreme surgical risk. However, both degree of residual regurgitation and gradient after the procedure should be taken into account, as in previous studies the latter was associated with<a href="https://solaci.org/en/2022/05/09/is-increased-mitral-valve-gradient-after-mitraclip-a-long-term-prognostic-factor/" title="Read more" >...</a>
EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System
The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for<a href="https://solaci.org/en/2021/05/26/europcr-2021-clasp-2-year-outcomes-of-the-new-mitral-valve-repair-system/" title="Read more" >...</a>
Improvements in COAPT Trial for Functional Mitral Regurgitation
Patients with heart failure and moderate-to-severe secondary mitral regurgitation may benefit from transcatheter mitral valve repair. There are benefits at 3 years, even in hard points such as mortality rate. The COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial showed fewer heart failure hospitalizations and<a href="https://solaci.org/en/2021/03/15/improvements-in-coapt-trial-for-functional-mitral-regurgitation/" title="Read more" >...</a>
Sapien Valve Keeps Delivering in Jobs for Which It Was Not Designed
We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has<a href="https://solaci.org/en/2020/12/16/sapien-valve-keeps-delivering-in-jobs-for-which-it-was-not-designed/" title="Read more" >...</a>
EuroPCR 2020 | CLASP: New Device for Mitral Repair with at One Year Follow Up
The CLASP looked into patients treated with the new device for transcatheter mitral repair called PASCAL and showed low complications rate, high survival rate, significant mitral regurgitation reduction and improved quality of life at one year. In July 2019 we published on our web page the 30 year outcomes of the PASCAL device () which<a href="https://solaci.org/en/2020/07/08/europcr-2020-clasp-new-device-for-mitral-repair-with-at-one-year-follow-up/" title="Read more" >...</a>
TAVR in Small Annuli: Is There a Better Valve?
Transcatheter aortic valve replacement with the self-expandable valves has shown optimal clinical and electrocardiographic results in patients with small annuli. These supra-annular prosthetic valves seem somewhat better than the intra-annular balloon expandable. TAVR in general has better functional results in terms of patient/prosthesis mismatch. This seems especially true for patients with a small annulus. The<a href="https://solaci.org/en/2020/03/20/tavr-in-small-annuli-is-there-a-better-valve/" title="Read more" >...</a>
Treating Both Atrial Valves Improves Survival
Courtesy of Dr. Carlos Fava. There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation. Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial<a href="https://solaci.org/en/2020/03/10/treating-both-atrial-valves-improves-survival/" title="Read more" >...</a>
More Evidence on Tricuspid Valve Repair
While still lacking large-scale randomized trials, evidence is slowly building for transcatheter tricuspid valve repair. This work, presented at the TCT 2019 Congress and simultaneously published in JACC, shows that transcatheter tricuspid valve repair is not only feasible, but also likely to reduce the rates of mortality and heart failure rehospitalization compared with medical therapy alone.<a href="https://solaci.org/en/2019/10/18/more-evidence-on-tricuspid-valve-repair/" title="Read more" >...</a>
TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses
Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had<a href="https://solaci.org/en/2019/09/30/tct-2019-mitral-valve-in-valve-1-year-results-for-sapien-3-in-mitral-valve-replacement-for-degenerated-bioprostheses/" title="Read more" >...</a>